Tempest Therapeutics (TPST) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

TPST · Stock Price

USD 1.97-4.90 (-71.32%)

Market Cap: $28.6M

Historical price data

Market Cap: $28.6MPipeline: 2 drugsFounded: 2011HQ: Brisbane, United States

Sector Ranking#317 in Small Molecule Drugs #63 in Immunotherapy / Immuno-Oncology

Overview

Tempest Therapeutics is advancing a novel oncology pipeline focused on overcoming resistance to immunotherapy by targeting tumor-intrinsic and immune-mediated pathways. Its lead candidate, TPST-1120, is in a global randomized Phase 1b/2 trial in combination with standard-of-care for frontline liver cancers, with recent data showing promising survival signals. The company's strategy is to develop oral, targeted agents that can be used as monotherapies or in combinations to improve outcomes for patients with advanced solid tumors. Despite a challenging financial position, Tempest is executing on key clinical readouts and pursuing strategic partnerships to advance its programs.

Oncology

Technology Platform

A rational drug design platform focused on developing oral small molecules that target key immunosuppressive pathways in the tumor microenvironment, specifically through metabolic modulation (PPARα antagonism) and prostaglandin pathway inhibition (EP2/EP4 dual antagonism).

Pipeline

2

2 drugs in pipeline

Drug	Indication	Stage	Watch
Part 1 TPST-1120 + Part 2 TPST-1120 + nivolumab + Part 3 TPS...	Hepatocellular Carcinoma	Phase 1
TPST-1495 twice daily + TPST-1495 once daily or on intermitt...	Solid Tumor	Phase 1

Opportunities

TPST-1120's randomized trials in first-line liver cancers (HCC and CCA) represent a direct shot at large markets with unmet need.

Positive overall survival data could position the asset as a valuable combination partner for the standard-of-care immunotherapy backbone, attracting partnership or acquisition interest.

The oral formulation of its candidates is a key differentiator for patient convenience.

Risk Factors

Extreme financial risk with very limited cash runway necessitates near-term dilutive financing or a value-creating partnership.

The company's valuation is almost entirely dependent on the success of TPST-1120 in ongoing randomized trials; negative data would be catastrophic.

As a micro-cap biotech, it faces intense competition from larger firms with greater resources.

Competitive Landscape

TPST-1120 is a first-in-class PPARα antagonist with limited direct competition but faces indirect competition from other metabolic modulators. TPST-1495, as a dual EP2/EP4 antagonist, competes in a more crowded prostaglandin pathway space against selective EP4 inhibitors. The primary competition is any therapy aiming to improve frontline immunotherapy outcomes in solid tumors.